No

Date

Investors/

Licensee

Service Provider/

Licensor

Assets

MoA

Indication

Stage

Value

(USD Mn)

1

4/7

Vertex

Pharmaceuticals

Halozyme

Hypercon Inc.

‘Hypercon’

Platform

Microparticle drug delivery

platform for use in up to 3

drug targets

n/d

n/d

Discovery

15+

2

4/7

Biogen

Alloy Therapeutics

‘AntiClastic’

Platform

Intracellular RNA‑targeting

ASO platform

n/d

n/d

Discovery

n/d

3

4/8

Astellas Pharma

Dyno Therapeutics

-

AAV gene therapy vectors/

capsids for skeletal and

cardiac muscle

-

-

Discovery

15+

4

4/9

Roche

C4 Therapeutics

‘Torpedo’

Platform

Degrader payload discovery

and optimization platform

for DAC development

Oncology

Cancer

Discovery

1,020

5

4/9

Boston Oncology

Xuanzhu Biopharmaceutical

Bireociclib

Dirozalkib

CDK2/4/6 inhibitor

ALK inhibitor

Oncology

Oncology

HER+/HER2- Breast cancer

ALK-positive NSCLC

Marketed

Marketed

100

6

4/9

BMS

Oxford

BioTherapeutics

‘OGAP®-Verify’ Platform

TCE platform against novel

tumor selective solid tumor

targets

Oncology

Solid tumors

Discovery

n/d

7

4/10

AbbVie

Haisco

Pharmaceutical

HSK55718

HSK51155

Nav1.8 inhibitor

Nav1.8 inhibitor

Neurology

Neurology

Pain

Pain

Phase 1

Preclinical

745

8

4/10

Gilead

Kymera

Therapeutics

KT-200

CDK2 molecular glue

degrader

Oncology

Solid tumors; Breast cancer

Preclinical

750

9

4/13

Regeneron

Telix

Pharmaceuticals

n/d

4 initial RPT programs +

optional 4 additional

programs

Oncology

Solid tumors

Discovery

2,100

10

4/16

Xiamen Amoytop

Aligos Therapeutics

Pevifoscorvir

sodium

Capsid Assembly Modulator-

Class E (CAM-E)

Infectious disease

Hepatitis B virus

Phase 2

445

11

4/20

Biogen

TJ Biopharma

Felzartamab

αCD38 mAb

Oncology

Multiple myeloma

Registration
(China)

850

12

4/28

Eli Lilly

Profluent

-

AI-designed site-specific

recombinases generator

n/d

n/d

Discovery

2,250

13

4/28

AbbVie

Kestrel Therapeutics

KST-6051

KRAS inhibitor

Oncology

KRAS-mutated advanced/
metastatic solid tumors

Phase 1

1,450

14

4/30

BeOne Medicines

Huahui Health

HH160

PD-1/CTLA-4/VEGF Trispecific

antibody

Oncology

Solid tumors

Preclinical

2,020

15

4/30

Cue Biopharma

Ascendant Health

Sciences

Ascendant-221

mAb with dual MoA : free IgE

neutralization + CD23-

mediated IgE production

suppression

Immunology

Allergic diseases

Phase 2

691.5

No

Date

Acquires

Issuer

Assets

MoA

Indications

Status

Value

(USD Mn)

1

3/31

Eli Lilly

Centessa Pharmaceuticals

Cleminorexton

OX2R agonist

Neurology

Narcolepsy(Type 1, 2),
Idiopathic hypersomnia

Phase 2a

7,800

2

3/31

Biogen

Apellis Pharmaceuticals

Syfovre

Empaveli

C3, C3b inhibitor

C3, C3b inhibitor

Ophthalmology

Hematology

GA

PNH

Marketed

Marketed

6,150

3

4/6

Neurocrine Biosciences

Soleno Therapeutics

Vykat XR

KATP agonist

Metabolic disorder

Prader-Willi syndrome

Marketed

2,900

4

4/7

Gilead Sciences

Tubulis GmbH

TUB-040

TUB-030

NaPi2b ADC

5T4 ADC

Oncology

Oncology

Ovarian cancer, NSCLC

Solid tumors

Phase 1b/2

Phase 1/2

5,000

5

4/14

Eli Lilly

CrossBridge Bio

CBB-120

TROP2-targeted Dual Payload 

ADC (TOP1i/ATRi)

Oncology

Solid tumors

Preclinical

300

6

4/17

UCB

Neurona Therapeutics

NRTX-1001

GABA interneuron cell therapy

Neurology

Epilepsy

Phase 1/2

1,150

7

4/20

Eli Lilly

Kelonia Therapeutics

KLN-1010

BCMA CAR-T

Oncology

Multiple myeloma

Phase 1

7,000

8

4/27

Eli Lilly

Ajax Therapeutics

AJ1-11095

JAK-2 inhibitor

Oncology

Myelofibrosis

Phase 1

2,300

9

4/29

Teva Pharmaceuticals

Emalex Biosciences

Ecopipam

DRD1 antagonist

Neurology

Tourette syndrome

Phase 3

900

10

4/29

Chiesi Group

KalVista

Ekterly

KLKB1 inhibitor

Immunology

Hereditary angioedema

Marketed

1,900

11

4/30

Leo Pharma

Replay

-

HSV-vectored topical gene

therapy platform

Dermatology

Genetic skin diseases

Preclinical

50+